Stocksigma LogoStocksigma Logo

Mukka Proteins Q2 FY27 Investor Presentation

Mukka Proteins reported consolidated Q2 FY27 revenue of ₹508.9 crore, up 108.1% YoY, with EBITDA rising 90.5% YoY to ₹50.1 crore (9.9% margin) and PAT

Mukka Proteins Q2 FY27 Investor Presentation

Mukka Proteins Ltd · Investor Presentation · 10 Nov 2026, 4:13 pm

Mukka Proteins Q2 FY27 Investor Presentation Mukka Proteins reported consolidated Q2 FY27 revenue of ₹508.9 crore, up 108.1% YoY, with EBITDA rising 90.5% YoY to ₹50.1 crore (9.9% margin) and PAT surging 156.5% YoY to ₹17.7 crore. For H1 FY27, revenue reached ₹998.5 crore with PAT of ₹36.3 crore. Exports contributed 81.3% of Q2 FY27 revenue. Operational milestones include commercial production at the 21,249 sq. mt Al Joubah facility in Oman with US FDA registration, and securing a ₹474.89 crore leachate treatment contract from BSWML. Management targets over ₹3,000 crore revenue by FY30.

Original exchange filing (PDF)

More announcements from Mukka Proteins Ltd

All Mukka Proteins Ltd announcements